US EditionPublished • loading... • Updated
The Search for an Investor Is Underway: This Is What Happens Next at R-Pharm After Insolvency.
Summary by Augsburger Allgemeine
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Illertissen – The German subsidiary of the Russian pharmaceutical company R-Pharm has filed for insolvency. According to the provisional insolvency administrator, Markus Fröhlich, the main reason is the sanctions imposed by the European Union (EU) in response to the war in Ukraine and the Russian countermeasures, which have unsettled customers and business partners.
The sale of the pharmaceutical company with Russian owners appeared to be nearing completion. Now, an insolvency administrator from Neu-Ulm is to manage the Illertissen plant.
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
